BIO-IDENTICAL HORMONES MARKET ANALYSIS
Global Bio-identical Hormones Market – Regional Insights
North America accounted for the largest market share in 2018 owing to launches and approvals of bio-identical hormones in the region. For instance, in September 2018, TherapeuticsMD, Inc., a pharmaceutical company, launched Imvexxy, (estradiol vaginal inserts) in the U.S. Imvexxy is used for treating moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), due to menopause. Moreover, in June 2019, TherapeuticsMD, Inc. announced a license and supply agreement with Theramex, a pharmaceutical company dedicated to women’s health, to commercialize IMVEXXY (estradiol vaginal inserts) and BIJUVA (estradiol and progesterone capsules) outside of the U.S., except in Canada and Israel.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 